Clare Legursky
Family Medicine · Woodstock, ILNPI 1417059007
Payments from drug & device makers
Across 148 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$341
- AbbVie$277
- Pfizer$195
- GSK$176
- Lilly USA, LLC$153
- AstraZeneca$149
- plus $987 from 22 others
What the payments were for
- Food & beverage$2,24999%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $341 |
| AbbVie(2 entities) | 20 | $277 |
| Pfizer | 14 | $195 |
| GSK | 12 | $176 |
| Lilly USA, LLC | 9 | $153 |
| AstraZeneca | 10 | $149 |
| Bayer | 8 | $132 |
| Sanofi-aventis U.S. LLC | 5 | $90 |
| Novartis | 6 | $90 |
| Johnson & Johnson | 6 | $90 |
| Abbott | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $63 |
| Boehringer Ingelheim | 4 | $55 |
| Dexcom, Inc. | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Nestle Healthcare Nutrition Inc. | 3 | $47 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Exact Sciences | 2 | $29 |
| Merck | 2 | $28 |
| Astellas Pharma US Inc | 2 | $24 |
| Mylan Specialty L.p. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$2,279 in reported general payments places this provider in the 80th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $31,911 |
| MounjaroTirzepatide | 23 | $23,498 |
| OzempicSemaglutide | 14 | $12,371 |
| Levothyroxine Sodium | 113 | $1,013 |
| SynthroidLevothyroxine Sodium | 19 | $933 |
| Atorvastatin Calcium | 116 | $879 |
| Celecoxib | 23 | $741 |
| Potassium Chloride | 49 | $695 |
| Pravastatin Sodium | 80 | $689 |
| Rosuvastatin Calcium | 59 | $689 |
| Gabapentin | 40 | $620 |
| Metoprolol Succinate | 48 | $616 |
| Escitalopram Oxalate | 46 | $584 |
| Lisinopril | 82 | $510 |
| Simvastatin | 50 | $489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $195 | $31,91130 claims |
| Lilly USA, LLCMounjaro | $153 | $23,49823 claims |
| Novo NordiskOzempic | $341 | $12,37114 claims |
| AbbVieSynthroid | $277 | $93319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Woodstock
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.